nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabigatran etexilate—UGT2B7—Epirubicin—testicular cancer	0.277	0.545	CbGbCtD
Dabigatran etexilate—F2—posterior vena cava—testicular cancer	0.091	0.457	CbGeAlD
Dabigatran etexilate—ABCB1—Dactinomycin—testicular cancer	0.0655	0.129	CbGbCtD
Dabigatran etexilate—ABCB1—Vinblastine—testicular cancer	0.041	0.0808	CbGbCtD
Dabigatran etexilate—F2—vein—testicular cancer	0.0402	0.202	CbGeAlD
Dabigatran etexilate—ABCB1—Cisplatin—testicular cancer	0.0376	0.0741	CbGbCtD
Dabigatran etexilate—ABCB1—Etoposide—testicular cancer	0.037	0.0728	CbGbCtD
Dabigatran etexilate—ABCB1—Doxorubicin—testicular cancer	0.0252	0.0497	CbGbCtD
Dabigatran etexilate—ABCB1—Methotrexate—testicular cancer	0.0244	0.0481	CbGbCtD
Dabigatran etexilate—CES2—seminal vesicle—testicular cancer	0.00797	0.04	CbGeAlD
Dabigatran etexilate—NQO2—seminal vesicle—testicular cancer	0.00712	0.0357	CbGeAlD
Dabigatran etexilate—CES2—gonad—testicular cancer	0.00576	0.0289	CbGeAlD
Dabigatran etexilate—CES2—female gonad—testicular cancer	0.00468	0.0235	CbGeAlD
Dabigatran etexilate—F2—female gonad—testicular cancer	0.0042	0.0211	CbGeAlD
Dabigatran etexilate—NQO2—female gonad—testicular cancer	0.00418	0.021	CbGeAlD
Dabigatran etexilate—CES2—testis—testicular cancer	0.00415	0.0208	CbGeAlD
Dabigatran etexilate—UGT2B7—testis—testicular cancer	0.00415	0.0208	CbGeAlD
Dabigatran etexilate—CES1—female gonad—testicular cancer	0.00385	0.0193	CbGeAlD
Dabigatran etexilate—NQO2—testis—testicular cancer	0.00371	0.0186	CbGeAlD
Dabigatran etexilate—CES1—testis—testicular cancer	0.00342	0.0172	CbGeAlD
Dabigatran etexilate—CES2—lymph node—testicular cancer	0.00301	0.0151	CbGeAlD
Dabigatran etexilate—NQO2—lymph node—testicular cancer	0.00269	0.0135	CbGeAlD
Dabigatran etexilate—CES1—lymph node—testicular cancer	0.00248	0.0124	CbGeAlD
Dabigatran etexilate—ABCB1—embryo—testicular cancer	0.00164	0.00821	CbGeAlD
Dabigatran etexilate—ABCB1—seminal vesicle—testicular cancer	0.00154	0.00772	CbGeAlD
Dabigatran etexilate—ABCB1—gonad—testicular cancer	0.00111	0.00558	CbGeAlD
Dabigatran etexilate—ABCB1—female gonad—testicular cancer	0.000902	0.00453	CbGeAlD
Dabigatran etexilate—ABCB1—testis—testicular cancer	0.0008	0.00402	CbGeAlD
Dabigatran etexilate—ABCB1—lymph node—testicular cancer	0.00058	0.00291	CbGeAlD
Dabigatran etexilate—Loss of consciousness—Etoposide—testicular cancer	0.000494	0.00169	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Cisplatin—testicular cancer	0.000492	0.00168	CcSEcCtD
Dabigatran etexilate—Cough—Etoposide—testicular cancer	0.000491	0.00167	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Cisplatin—testicular cancer	0.000491	0.00167	CcSEcCtD
Dabigatran etexilate—Asthenia—Bleomycin—testicular cancer	0.000488	0.00166	CcSEcCtD
Dabigatran etexilate—Skin disorder—Cisplatin—testicular cancer	0.000487	0.00166	CcSEcCtD
Dabigatran etexilate—Hypertension—Etoposide—testicular cancer	0.000486	0.00166	CcSEcCtD
Dabigatran etexilate—Osteoarthritis—Doxorubicin—testicular cancer	0.000485	0.00165	CcSEcCtD
Dabigatran etexilate—Pain in extremity—Doxorubicin—testicular cancer	0.000485	0.00165	CcSEcCtD
Dabigatran etexilate—Gastrointestinal haemorrhage—Doxorubicin—testicular cancer	0.000485	0.00165	CcSEcCtD
Dabigatran etexilate—Liver function test abnormal—Epirubicin—testicular cancer	0.000483	0.00165	CcSEcCtD
Dabigatran etexilate—Pruritus—Bleomycin—testicular cancer	0.000481	0.00164	CcSEcCtD
Dabigatran etexilate—Chest pain—Etoposide—testicular cancer	0.000479	0.00163	CcSEcCtD
Dabigatran etexilate—Nausea—Vinblastine—testicular cancer	0.000478	0.00163	CcSEcCtD
Dabigatran etexilate—Abdominal pain upper—Epirubicin—testicular cancer	0.000478	0.00163	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Etoposide—testicular cancer	0.000476	0.00162	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Ifosfamide—testicular cancer	0.000475	0.00162	CcSEcCtD
Dabigatran etexilate—Aspartate aminotransferase increased—Epirubicin—testicular cancer	0.000472	0.00161	CcSEcCtD
Dabigatran etexilate—Hypotension—Cisplatin—testicular cancer	0.000468	0.0016	CcSEcCtD
Dabigatran etexilate—Nasopharyngitis—Epirubicin—testicular cancer	0.000468	0.0016	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Dactinomycin—testicular cancer	0.000467	0.00159	CcSEcCtD
Dabigatran etexilate—Abdominal discomfort—Methotrexate—testicular cancer	0.000464	0.00158	CcSEcCtD
Dabigatran etexilate—Gastritis—Epirubicin—testicular cancer	0.000463	0.00158	CcSEcCtD
Dabigatran etexilate—Alanine aminotransferase increased—Epirubicin—testicular cancer	0.000462	0.00158	CcSEcCtD
Dabigatran etexilate—Urticaria—Ifosfamide—testicular cancer	0.000462	0.00158	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Ifosfamide—testicular cancer	0.00046	0.00157	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Etoposide—testicular cancer	0.000459	0.00157	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Cisplatin—testicular cancer	0.000457	0.00156	CcSEcCtD
Dabigatran etexilate—Infection—Etoposide—testicular cancer	0.000456	0.00156	CcSEcCtD
Dabigatran etexilate—Asthenia—Dactinomycin—testicular cancer	0.000455	0.00155	CcSEcCtD
Dabigatran etexilate—Influenza—Epirubicin—testicular cancer	0.000453	0.00154	CcSEcCtD
Dabigatran etexilate—Dysphagia—Epirubicin—testicular cancer	0.000453	0.00154	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Etoposide—testicular cancer	0.00045	0.00153	CcSEcCtD
Dabigatran etexilate—Upper respiratory tract infection—Methotrexate—testicular cancer	0.000449	0.00153	CcSEcCtD
Dabigatran etexilate—Liver function test abnormal—Doxorubicin—testicular cancer	0.000447	0.00153	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Cisplatin—testicular cancer	0.000447	0.00152	CcSEcCtD
Dabigatran etexilate—Skin disorder—Etoposide—testicular cancer	0.000446	0.00152	CcSEcCtD
Dabigatran etexilate—Abdominal pain upper—Doxorubicin—testicular cancer	0.000443	0.00151	CcSEcCtD
Dabigatran etexilate—Angina pectoris—Epirubicin—testicular cancer	0.000441	0.0015	CcSEcCtD
Dabigatran etexilate—Aspartate aminotransferase increased—Doxorubicin—testicular cancer	0.000436	0.00149	CcSEcCtD
Dabigatran etexilate—Bronchitis—Epirubicin—testicular cancer	0.000435	0.00148	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Dactinomycin—testicular cancer	0.000434	0.00148	CcSEcCtD
Dabigatran etexilate—Pneumonia—Methotrexate—testicular cancer	0.000434	0.00148	CcSEcCtD
Dabigatran etexilate—Nasopharyngitis—Doxorubicin—testicular cancer	0.000433	0.00148	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Cisplatin—testicular cancer	0.000433	0.00148	CcSEcCtD
Dabigatran etexilate—Vomiting—Bleomycin—testicular cancer	0.000433	0.00148	CcSEcCtD
Dabigatran etexilate—Infestation NOS—Methotrexate—testicular cancer	0.000431	0.00147	CcSEcCtD
Dabigatran etexilate—Infestation—Methotrexate—testicular cancer	0.000431	0.00147	CcSEcCtD
Dabigatran etexilate—Hypotension—Etoposide—testicular cancer	0.000429	0.00146	CcSEcCtD
Dabigatran etexilate—Rash—Bleomycin—testicular cancer	0.000429	0.00146	CcSEcCtD
Dabigatran etexilate—Gastritis—Doxorubicin—testicular cancer	0.000429	0.00146	CcSEcCtD
Dabigatran etexilate—Dermatitis—Bleomycin—testicular cancer	0.000429	0.00146	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Ifosfamide—testicular cancer	0.000428	0.00146	CcSEcCtD
Dabigatran etexilate—Alanine aminotransferase increased—Doxorubicin—testicular cancer	0.000427	0.00146	CcSEcCtD
Dabigatran etexilate—Upper respiratory tract infection—Epirubicin—testicular cancer	0.000421	0.00143	CcSEcCtD
Dabigatran etexilate—Influenza—Doxorubicin—testicular cancer	0.000419	0.00143	CcSEcCtD
Dabigatran etexilate—Dysphagia—Doxorubicin—testicular cancer	0.000419	0.00143	CcSEcCtD
Dabigatran etexilate—Asthenia—Ifosfamide—testicular cancer	0.000417	0.00142	CcSEcCtD
Dabigatran etexilate—Pruritus—Ifosfamide—testicular cancer	0.000411	0.0014	CcSEcCtD
Dabigatran etexilate—Haematuria—Methotrexate—testicular cancer	0.000411	0.0014	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Etoposide—testicular cancer	0.000409	0.0014	CcSEcCtD
Dabigatran etexilate—Angina pectoris—Doxorubicin—testicular cancer	0.000408	0.00139	CcSEcCtD
Dabigatran etexilate—Hepatobiliary disease—Methotrexate—testicular cancer	0.000408	0.00139	CcSEcCtD
Dabigatran etexilate—Epistaxis—Methotrexate—testicular cancer	0.000407	0.00139	CcSEcCtD
Dabigatran etexilate—Pneumonia—Epirubicin—testicular cancer	0.000406	0.00138	CcSEcCtD
Dabigatran etexilate—Nausea—Bleomycin—testicular cancer	0.000404	0.00138	CcSEcCtD
Dabigatran etexilate—Infestation NOS—Epirubicin—testicular cancer	0.000404	0.00138	CcSEcCtD
Dabigatran etexilate—Infestation—Epirubicin—testicular cancer	0.000404	0.00138	CcSEcCtD
Dabigatran etexilate—Vomiting—Dactinomycin—testicular cancer	0.000403	0.00138	CcSEcCtD
Dabigatran etexilate—Bronchitis—Doxorubicin—testicular cancer	0.000403	0.00137	CcSEcCtD
Dabigatran etexilate—Rash—Dactinomycin—testicular cancer	0.0004	0.00136	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Ifosfamide—testicular cancer	0.000398	0.00136	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Etoposide—testicular cancer	0.000396	0.00135	CcSEcCtD
Dabigatran etexilate—Fatigue—Etoposide—testicular cancer	0.000396	0.00135	CcSEcCtD
Dabigatran etexilate—Constipation—Etoposide—testicular cancer	0.000393	0.00134	CcSEcCtD
Dabigatran etexilate—Urinary tract infection—Epirubicin—testicular cancer	0.000392	0.00134	CcSEcCtD
Dabigatran etexilate—Upper respiratory tract infection—Doxorubicin—testicular cancer	0.000389	0.00133	CcSEcCtD
Dabigatran etexilate—Haemoglobin—Methotrexate—testicular cancer	0.000389	0.00133	CcSEcCtD
Dabigatran etexilate—Haemorrhage—Methotrexate—testicular cancer	0.000387	0.00132	CcSEcCtD
Dabigatran etexilate—Haematuria—Epirubicin—testicular cancer	0.000385	0.00131	CcSEcCtD
Dabigatran etexilate—Dizziness—Ifosfamide—testicular cancer	0.000384	0.00131	CcSEcCtD
Dabigatran etexilate—Urinary tract disorder—Methotrexate—testicular cancer	0.000382	0.0013	CcSEcCtD
Dabigatran etexilate—Hepatobiliary disease—Epirubicin—testicular cancer	0.000382	0.0013	CcSEcCtD
Dabigatran etexilate—Epistaxis—Epirubicin—testicular cancer	0.000381	0.0013	CcSEcCtD
Dabigatran etexilate—Urethral disorder—Methotrexate—testicular cancer	0.000379	0.00129	CcSEcCtD
Dabigatran etexilate—Sinusitis—Epirubicin—testicular cancer	0.000379	0.00129	CcSEcCtD
Dabigatran etexilate—Nausea—Dactinomycin—testicular cancer	0.000377	0.00129	CcSEcCtD
Dabigatran etexilate—Pneumonia—Doxorubicin—testicular cancer	0.000376	0.00128	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Etoposide—testicular cancer	0.000375	0.00128	CcSEcCtD
Dabigatran etexilate—Infestation—Doxorubicin—testicular cancer	0.000373	0.00127	CcSEcCtD
Dabigatran etexilate—Infestation NOS—Doxorubicin—testicular cancer	0.000373	0.00127	CcSEcCtD
Dabigatran etexilate—Vomiting—Ifosfamide—testicular cancer	0.00037	0.00126	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Cisplatin—testicular cancer	0.000369	0.00126	CcSEcCtD
Dabigatran etexilate—Rash—Ifosfamide—testicular cancer	0.000367	0.00125	CcSEcCtD
Dabigatran etexilate—Dermatitis—Ifosfamide—testicular cancer	0.000366	0.00125	CcSEcCtD
Dabigatran etexilate—Urticaria—Etoposide—testicular cancer	0.000365	0.00124	CcSEcCtD
Dabigatran etexilate—Haemoglobin—Epirubicin—testicular cancer	0.000364	0.00124	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Etoposide—testicular cancer	0.000363	0.00124	CcSEcCtD
Dabigatran etexilate—Urinary tract infection—Doxorubicin—testicular cancer	0.000363	0.00124	CcSEcCtD
Dabigatran etexilate—Haemorrhage—Epirubicin—testicular cancer	0.000362	0.00124	CcSEcCtD
Dabigatran etexilate—Asthenia—Cisplatin—testicular cancer	0.00036	0.00123	CcSEcCtD
Dabigatran etexilate—Cardiac disorder—Methotrexate—testicular cancer	0.000359	0.00123	CcSEcCtD
Dabigatran etexilate—Urinary tract disorder—Epirubicin—testicular cancer	0.000358	0.00122	CcSEcCtD
Dabigatran etexilate—Oedema peripheral—Epirubicin—testicular cancer	0.000357	0.00122	CcSEcCtD
Dabigatran etexilate—Haematuria—Doxorubicin—testicular cancer	0.000356	0.00121	CcSEcCtD
Dabigatran etexilate—Connective tissue disorder—Epirubicin—testicular cancer	0.000356	0.00121	CcSEcCtD
Dabigatran etexilate—Urethral disorder—Epirubicin—testicular cancer	0.000355	0.00121	CcSEcCtD
Dabigatran etexilate—Hepatobiliary disease—Doxorubicin—testicular cancer	0.000353	0.0012	CcSEcCtD
Dabigatran etexilate—Epistaxis—Doxorubicin—testicular cancer	0.000352	0.0012	CcSEcCtD
Dabigatran etexilate—Angiopathy—Methotrexate—testicular cancer	0.000351	0.0012	CcSEcCtD
Dabigatran etexilate—Sinusitis—Doxorubicin—testicular cancer	0.00035	0.00119	CcSEcCtD
Dabigatran etexilate—Immune system disorder—Methotrexate—testicular cancer	0.00035	0.00119	CcSEcCtD
Dabigatran etexilate—Mediastinal disorder—Methotrexate—testicular cancer	0.000349	0.00119	CcSEcCtD
Dabigatran etexilate—Nausea—Ifosfamide—testicular cancer	0.000345	0.00118	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Cisplatin—testicular cancer	0.000343	0.00117	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Etoposide—testicular cancer	0.000338	0.00115	CcSEcCtD
Dabigatran etexilate—Malnutrition—Methotrexate—testicular cancer	0.000337	0.00115	CcSEcCtD
Dabigatran etexilate—Haemoglobin—Doxorubicin—testicular cancer	0.000337	0.00115	CcSEcCtD
Dabigatran etexilate—Cardiac disorder—Epirubicin—testicular cancer	0.000336	0.00115	CcSEcCtD
Dabigatran etexilate—Haemorrhage—Doxorubicin—testicular cancer	0.000335	0.00114	CcSEcCtD
Dabigatran etexilate—Urinary tract disorder—Doxorubicin—testicular cancer	0.000331	0.00113	CcSEcCtD
Dabigatran etexilate—Oedema peripheral—Doxorubicin—testicular cancer	0.00033	0.00113	CcSEcCtD
Dabigatran etexilate—Asthenia—Etoposide—testicular cancer	0.000329	0.00112	CcSEcCtD
Dabigatran etexilate—Connective tissue disorder—Doxorubicin—testicular cancer	0.000329	0.00112	CcSEcCtD
Dabigatran etexilate—Angiopathy—Epirubicin—testicular cancer	0.000329	0.00112	CcSEcCtD
Dabigatran etexilate—Urethral disorder—Doxorubicin—testicular cancer	0.000329	0.00112	CcSEcCtD
Dabigatran etexilate—Immune system disorder—Epirubicin—testicular cancer	0.000327	0.00112	CcSEcCtD
Dabigatran etexilate—Mediastinal disorder—Epirubicin—testicular cancer	0.000326	0.00111	CcSEcCtD
Dabigatran etexilate—Back pain—Methotrexate—testicular cancer	0.000326	0.00111	CcSEcCtD
Dabigatran etexilate—Pruritus—Etoposide—testicular cancer	0.000325	0.00111	CcSEcCtD
Dabigatran etexilate—Vomiting—Cisplatin—testicular cancer	0.000319	0.00109	CcSEcCtD
Dabigatran etexilate—Rash—Cisplatin—testicular cancer	0.000316	0.00108	CcSEcCtD
Dabigatran etexilate—Dermatitis—Cisplatin—testicular cancer	0.000316	0.00108	CcSEcCtD
Dabigatran etexilate—Malnutrition—Epirubicin—testicular cancer	0.000315	0.00108	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Etoposide—testicular cancer	0.000314	0.00107	CcSEcCtD
Dabigatran etexilate—Anaemia—Methotrexate—testicular cancer	0.000311	0.00106	CcSEcCtD
Dabigatran etexilate—Cardiac disorder—Doxorubicin—testicular cancer	0.000311	0.00106	CcSEcCtD
Dabigatran etexilate—Flatulence—Epirubicin—testicular cancer	0.000311	0.00106	CcSEcCtD
Dabigatran etexilate—Back pain—Epirubicin—testicular cancer	0.000305	0.00104	CcSEcCtD
Dabigatran etexilate—Angiopathy—Doxorubicin—testicular cancer	0.000304	0.00104	CcSEcCtD
Dabigatran etexilate—Dizziness—Etoposide—testicular cancer	0.000304	0.00104	CcSEcCtD
Dabigatran etexilate—Immune system disorder—Doxorubicin—testicular cancer	0.000303	0.00103	CcSEcCtD
Dabigatran etexilate—Mediastinal disorder—Doxorubicin—testicular cancer	0.000302	0.00103	CcSEcCtD
Dabigatran etexilate—Nausea—Cisplatin—testicular cancer	0.000298	0.00102	CcSEcCtD
Dabigatran etexilate—Cough—Methotrexate—testicular cancer	0.000294	0.001	CcSEcCtD
Dabigatran etexilate—Vomiting—Etoposide—testicular cancer	0.000292	0.000996	CcSEcCtD
Dabigatran etexilate—Malnutrition—Doxorubicin—testicular cancer	0.000292	0.000995	CcSEcCtD
Dabigatran etexilate—Anaemia—Epirubicin—testicular cancer	0.000291	0.000994	CcSEcCtD
Dabigatran etexilate—Rash—Etoposide—testicular cancer	0.00029	0.000987	CcSEcCtD
Dabigatran etexilate—Dermatitis—Etoposide—testicular cancer	0.000289	0.000987	CcSEcCtD
Dabigatran etexilate—Headache—Etoposide—testicular cancer	0.000288	0.000981	CcSEcCtD
Dabigatran etexilate—Flatulence—Doxorubicin—testicular cancer	0.000288	0.000981	CcSEcCtD
Dabigatran etexilate—Chest pain—Methotrexate—testicular cancer	0.000287	0.000979	CcSEcCtD
Dabigatran etexilate—Arthralgia—Methotrexate—testicular cancer	0.000287	0.000979	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000285	0.000972	CcSEcCtD
Dabigatran etexilate—Syncope—Epirubicin—testicular cancer	0.000283	0.000965	CcSEcCtD
Dabigatran etexilate—Back pain—Doxorubicin—testicular cancer	0.000282	0.000963	CcSEcCtD
Dabigatran etexilate—Palpitations—Epirubicin—testicular cancer	0.000279	0.000951	CcSEcCtD
Dabigatran etexilate—Loss of consciousness—Epirubicin—testicular cancer	0.000277	0.000945	CcSEcCtD
Dabigatran etexilate—Cough—Epirubicin—testicular cancer	0.000275	0.000939	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Methotrexate—testicular cancer	0.000275	0.000938	CcSEcCtD
Dabigatran etexilate—Infection—Methotrexate—testicular cancer	0.000273	0.000932	CcSEcCtD
Dabigatran etexilate—Nausea—Etoposide—testicular cancer	0.000273	0.00093	CcSEcCtD
Dabigatran etexilate—Hypertension—Epirubicin—testicular cancer	0.000272	0.000929	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Methotrexate—testicular cancer	0.00027	0.00092	CcSEcCtD
Dabigatran etexilate—Anaemia—Doxorubicin—testicular cancer	0.00027	0.00092	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Methotrexate—testicular cancer	0.000269	0.000918	CcSEcCtD
Dabigatran etexilate—Arthralgia—Epirubicin—testicular cancer	0.000268	0.000916	CcSEcCtD
Dabigatran etexilate—Chest pain—Epirubicin—testicular cancer	0.000268	0.000916	CcSEcCtD
Dabigatran etexilate—Skin disorder—Methotrexate—testicular cancer	0.000267	0.000911	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000267	0.000909	CcSEcCtD
Dabigatran etexilate—Syncope—Doxorubicin—testicular cancer	0.000262	0.000893	CcSEcCtD
Dabigatran etexilate—Palpitations—Doxorubicin—testicular cancer	0.000258	0.00088	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Epirubicin—testicular cancer	0.000257	0.000878	CcSEcCtD
Dabigatran etexilate—Hypotension—Methotrexate—testicular cancer	0.000257	0.000877	CcSEcCtD
Dabigatran etexilate—Loss of consciousness—Doxorubicin—testicular cancer	0.000256	0.000875	CcSEcCtD
Dabigatran etexilate—Infection—Epirubicin—testicular cancer	0.000256	0.000872	CcSEcCtD
Dabigatran etexilate—Cough—Doxorubicin—testicular cancer	0.000255	0.000868	CcSEcCtD
Dabigatran etexilate—Shock—Epirubicin—testicular cancer	0.000253	0.000864	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Epirubicin—testicular cancer	0.000252	0.000861	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Epirubicin—testicular cancer	0.000252	0.00086	CcSEcCtD
Dabigatran etexilate—Hypertension—Doxorubicin—testicular cancer	0.000252	0.000859	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.000251	0.000855	CcSEcCtD
Dabigatran etexilate—Skin disorder—Epirubicin—testicular cancer	0.00025	0.000853	CcSEcCtD
Dabigatran etexilate—Chest pain—Doxorubicin—testicular cancer	0.000248	0.000847	CcSEcCtD
Dabigatran etexilate—Arthralgia—Doxorubicin—testicular cancer	0.000248	0.000847	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.000247	0.000841	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Methotrexate—testicular cancer	0.000245	0.000836	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Methotrexate—testicular cancer	0.000242	0.000826	CcSEcCtD
Dabigatran etexilate—Hypotension—Epirubicin—testicular cancer	0.000241	0.00082	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Doxorubicin—testicular cancer	0.000238	0.000812	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000237	0.00081	CcSEcCtD
Dabigatran etexilate—Fatigue—Methotrexate—testicular cancer	0.000237	0.000809	CcSEcCtD
Dabigatran etexilate—Infection—Doxorubicin—testicular cancer	0.000237	0.000807	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.000234	0.0008	CcSEcCtD
Dabigatran etexilate—Shock—Doxorubicin—testicular cancer	0.000234	0.000799	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Doxorubicin—testicular cancer	0.000234	0.000797	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Doxorubicin—testicular cancer	0.000233	0.000795	CcSEcCtD
Dabigatran etexilate—Skin disorder—Doxorubicin—testicular cancer	0.000231	0.000789	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Epirubicin—testicular cancer	0.000229	0.000783	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Epirubicin—testicular cancer	0.000227	0.000773	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Methotrexate—testicular cancer	0.000225	0.000767	CcSEcCtD
Dabigatran etexilate—Hypotension—Doxorubicin—testicular cancer	0.000223	0.000759	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000222	0.000758	CcSEcCtD
Dabigatran etexilate—Fatigue—Epirubicin—testicular cancer	0.000222	0.000757	CcSEcCtD
Dabigatran etexilate—Constipation—Epirubicin—testicular cancer	0.00022	0.000751	CcSEcCtD
Dabigatran etexilate—Urticaria—Methotrexate—testicular cancer	0.000218	0.000745	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Methotrexate—testicular cancer	0.000217	0.000742	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.000217	0.00074	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Doxorubicin—testicular cancer	0.000212	0.000724	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Epirubicin—testicular cancer	0.00021	0.000718	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Doxorubicin—testicular cancer	0.00021	0.000715	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000206	0.000701	CcSEcCtD
Dabigatran etexilate—Fatigue—Doxorubicin—testicular cancer	0.000205	0.0007	CcSEcCtD
Dabigatran etexilate—Urticaria—Epirubicin—testicular cancer	0.000204	0.000697	CcSEcCtD
Dabigatran etexilate—Constipation—Doxorubicin—testicular cancer	0.000204	0.000695	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Epirubicin—testicular cancer	0.000203	0.000694	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Methotrexate—testicular cancer	0.000203	0.000691	CcSEcCtD
Dabigatran etexilate—Asthenia—Methotrexate—testicular cancer	0.000197	0.000673	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Doxorubicin—testicular cancer	0.000195	0.000664	CcSEcCtD
Dabigatran etexilate—Pruritus—Methotrexate—testicular cancer	0.000195	0.000664	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Epirubicin—testicular cancer	0.00019	0.000647	CcSEcCtD
Dabigatran etexilate—Urticaria—Doxorubicin—testicular cancer	0.000189	0.000645	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Doxorubicin—testicular cancer	0.000188	0.000642	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Methotrexate—testicular cancer	0.000188	0.000642	CcSEcCtD
Dabigatran etexilate—Asthenia—Epirubicin—testicular cancer	0.000185	0.00063	CcSEcCtD
Dabigatran etexilate—Pruritus—Epirubicin—testicular cancer	0.000182	0.000621	CcSEcCtD
Dabigatran etexilate—Dizziness—Methotrexate—testicular cancer	0.000182	0.00062	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Epirubicin—testicular cancer	0.000176	0.000601	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Doxorubicin—testicular cancer	0.000175	0.000598	CcSEcCtD
Dabigatran etexilate—Vomiting—Methotrexate—testicular cancer	0.000175	0.000596	CcSEcCtD
Dabigatran etexilate—Rash—Methotrexate—testicular cancer	0.000173	0.000591	CcSEcCtD
Dabigatran etexilate—Dermatitis—Methotrexate—testicular cancer	0.000173	0.000591	CcSEcCtD
Dabigatran etexilate—Headache—Methotrexate—testicular cancer	0.000172	0.000588	CcSEcCtD
Dabigatran etexilate—Asthenia—Doxorubicin—testicular cancer	0.000171	0.000583	CcSEcCtD
Dabigatran etexilate—Dizziness—Epirubicin—testicular cancer	0.00017	0.000581	CcSEcCtD
Dabigatran etexilate—Pruritus—Doxorubicin—testicular cancer	0.000168	0.000575	CcSEcCtD
Dabigatran etexilate—Vomiting—Epirubicin—testicular cancer	0.000164	0.000558	CcSEcCtD
Dabigatran etexilate—Nausea—Methotrexate—testicular cancer	0.000163	0.000557	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Doxorubicin—testicular cancer	0.000163	0.000556	CcSEcCtD
Dabigatran etexilate—Rash—Epirubicin—testicular cancer	0.000162	0.000554	CcSEcCtD
Dabigatran etexilate—Dermatitis—Epirubicin—testicular cancer	0.000162	0.000553	CcSEcCtD
Dabigatran etexilate—Headache—Epirubicin—testicular cancer	0.000161	0.00055	CcSEcCtD
Dabigatran etexilate—Dizziness—Doxorubicin—testicular cancer	0.000157	0.000537	CcSEcCtD
Dabigatran etexilate—Nausea—Epirubicin—testicular cancer	0.000153	0.000521	CcSEcCtD
Dabigatran etexilate—Vomiting—Doxorubicin—testicular cancer	0.000151	0.000516	CcSEcCtD
Dabigatran etexilate—Rash—Doxorubicin—testicular cancer	0.00015	0.000512	CcSEcCtD
Dabigatran etexilate—Dermatitis—Doxorubicin—testicular cancer	0.00015	0.000512	CcSEcCtD
Dabigatran etexilate—Headache—Doxorubicin—testicular cancer	0.000149	0.000509	CcSEcCtD
Dabigatran etexilate—Nausea—Doxorubicin—testicular cancer	0.000141	0.000482	CcSEcCtD
